Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9618MR)

This product GTTS-WQ9618MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9618MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ934MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ2507MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ6607MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ7278MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7055MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ8034MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9883MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ967MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW